Key facts
- This page summarizes William John Scheessele's Form 4 filing for Humacyte, Inc. (HUMA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 15 Apr 2025, 16:03.
William John Scheessele - 14 Apr 2025 Form 4 Insider Report for Humacyte, Inc. (HUMA)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- HUMA
- Reported as of
- 14 Apr 2025
- Net transaction value
- +$9,999
- SEC form
- 4
- Accepted by SEC
- 15 Apr 2025, 16:03:35 UTC
- Prior SEC filing
- 23 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ William John Scheessele by Dale A. Sander as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
William John Scheessele filed Form 4 for Humacyte, Inc. (HUMA) on 15 Apr 2025.
Change
- Previous filing in this sequence was filed on 23 Jan 2025.
- Current net transaction value: +$9,999.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HUMA
transaction
Common Stock
Purchase
- Transaction value
- $9,999
- Shares
- +6,493
- Change %
- +42%
- Price
- $1.54
- Shares after
- 22,018
- Date
- 14 Apr 2025
- Ownership
- Direct
* marks a reported price that did not pass the local price check.